CALGARY, AB, May 31, 2021 – Kailo Medical, a healthcare technology company with products that streamline structured reporting in the hospital setting, today announces its integration with Medo, an Artificial Intelligence company dual-headquartered in Singapore and Edmonton. The integration will see Medo Thyroid integrated into Kailo’s SonoReview product to make nodule classification quicker, simpler and more accurate, ultimately leading to better outcomes for patients.
Kailo Medical Integrates with Medo AI to Standardize Thyroid Ultrasound Practices
Kailo Medical announces an integration with Medo AI, bringing AI-powered thyroid nodule classification directly into Kailo's SonoReview product — using TI-RADS classification to make ultrasound assessment quicker, simpler, and more accurate for better patient outcomes.
“Kailo’s SonoReview is a powerful tool that streamlines structured reporting for radiologists worldwide. The integration of MEDO’s AI technology has the potential to double patient throughput and enable technologists and radiologists to more accurately assess, categorize and diagnose radiology findings, doing away with unnecessary follow up testing that can bring patients anxiety and stress.”
– Jessica Wilson, VP North America at Kailo Medical
The collaboration with Medo leverages AI and machine learning to analyze, assess and categorize thyroid ultrasound imaging using TI-RADS classification, all powered by the structured reporting delivered by Kailo’s SonoReview. The paired technologies enable technologists and radiologists to make more informed and confident decisions, standardise diagnoses and over time, reduce margin of error to deliver better health outcomes for all.
“The integration of the two solutions allows users to benefit from Kailo Medical’s efficiency gains as well as MEDO’s AI assistance, all seamlessly integrated within their workflow. The union of these two groundbreaking technologies is set to deliver a better user and patient experience.”
– David Quail, Co-Founder at MEDO.ai